NANCY LOUISE BECK M.D.
Prescription History 1124205513
Pediatrics - Pediatric Endocrinology in Lubbock, TX


Quality Rating: 100 out of 100 score

NPI Status: Active since January 28, 2008

Contact Information

4102 24TH ST STE 507
LUBBOCK, TX
ZIP 79410
Phone: (806) 743-7334
Fax: (806) 743-7332

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for NANCY LOUISE BECK M.D., an active Pediatric Endocrinology specialist practicing in Lubbock, TX. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 13 documented patient claims. Among these therapy options, the most frequently utilized medication is Levothyroxine Sodium, which accounts for 13 claims alone.

Medication Index

No matching medications currently found on file.

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.0
Days Supply 450
TX State Average Benchmarks
Peer Average Claims144.0
Peer Average 30-Day Fills342.9
Peer Average Days Supply10,129
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 91.0% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $151.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.65

State Avg Cost Per Claim

$17.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like NANCY LOUISE BECK M.D. provides transparency into local medical care patterns within Lubbock, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pediatric Endocrinology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.